Replies to post #235206 on Biotech Values

[DewDiligence]

MRK submits BLA/MAA for V114 pneumococcal vaccine in adults:

https://finance.yahoo.com/news/merck-submits-applications-licensure-v114-114700204.html

Many investors and analysts think PFE’s Prevnar 20, which covers five more serotypes than V114, will make V114 commercially irrelevant (#msg-154634395).